Skip to content

Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia

Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02687581
Enrollment
18
Registered
2016-02-22
Start date
2016-12-19
Completion date
2021-05-30
Last updated
2022-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia

Brief summary

This study is designed to evaluate the effectiveness of a novel amblyopia treatment - Intermittent occlusion therapy (IO-therapy) glasses (AmblyzTM) in treating severe amblyopia. Children ages 3 to 8 years with severe amblyopia (visual acuity of 20/100 to 20/400 in the amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour patching group or 2) 12-hour IO-therapy glasses group. The study also observe the effectiveness of IO-therapy glasses on two types of difficult amblyopia: deprivation amblyopia associated with congenital or developmental cataract, and myopic anisometropic amblyopia.

Detailed description

Children ages 3 to \< 8 years with severe/dense amblyopia (visual acuity of 20/100 to 20/400 in the amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour patching group or 2) 12-hour IO-therapy glasses group. Children ages 3 to \< 8 years with deprivation amblyopia associated with congenital or developmental cataracts (visual acuity of 20/40 to 20/400 in the amblyopic eye) will be enrolled. Children ages 3 to \< 8 years with myopic anisometropic amblyopia will be enrolled into an intermittent occlusion therapy glasses (AmblyzTM) group. According to visual acuity, they will receive one of two IO-therapy glasses treatment regimens: 1) If the amblyopic eye is between 20/40 to 20/80 inclusive, 4-hour IO-therapy glasses or 2) If the amblyopic eye is between 20/100 to 20/400 inclusive, the child will receive12-hour IO-therapy glasses.

Interventions

12-hour of 50% intermittent occlusion therapy on the fellow eye.

DEVICEpatch

6-hour of eye patch on the fellow eye

Sponsors

Indiana University
CollaboratorOTHER
Salus University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 8 Years
Healthy volunteers
No

Inclusion criteria

1. Age 3 to \< 8 years 2. Amblyopia associated with strabismus, anisometropia, or both 3. Visual acuity, measured in each eye without cycloplegia within 7 days prior to enrollment using the ATS single-surround HOTV letter protocol as follows: * Visual acuity in the amblyopic eye between 20/100 and 20/400 inclusive * Visual acuity in the sound eye 20/32 or better 4. Spectacle correction (if applicable) for measurement of enrollment visual acuity must meet the following criteria and be based on a cycloplegic refraction within 6 months: * Requirements for spectacle correction: * For patients meeting criteria for only strabismus i. Hypermetropia if corrected must not be undercorrected by more than +1.50 D spherical equivalent, and the reduction in plus sphere must be symmetric in the two eyes. Otherwise, spectacle correction is at investigator discretion. * For patients meeting criteria for anisometropia or combined-mechanism i. Spherical equivalent must be within 0.50 D of fully correcting the anisometropia ii. Hypermetropia must not be undercorrected by more than +1.50 D spherical equivalent, and reduction in plus must be symmetric in the two eyes iii. Cylinder power in both eyes must be within 0.50 D of fully correcting the astigmatism iv. Cylinder axis in the spectacle lenses in both eyes must be within 6 degrees of the axis of the cycloplegic refraction 5. Wearing optimal spectacle correction for a minimum of 4 weeks at the time of enrollment. 6. Gestational age \> 34 weeks and birth weight \> 1500 grams 7. Parent willing to accept randomization 8. Parent willing to be contacted and has access to phone 9. Parent does not anticipate relocation outside area of active study site

Exclusion criteria

* • Amblyopic eye has myopia worse than -3.00D spherical equivalent. * Previous amblyopia treatment within 6 months. * Prior intraocular or refractive surgery * Known skin reactions to patch or bandage adhesives * Systemic diseases that may cause reduced vision such as Down syndrome. If patients are in the deprivation amblyopia category, the following criteria must be met for the patient to be enrolled in the study: 1. Age 3 to \< 8 years 2. Amblyopia due to previous congenital or developmental cataract surgery. 3. Visual acuity, measured in each eye without cycloplegia within 7 days prior to enrollment using the ATS single-surround HOTV letter protocol as follows: a. Visual acuity in the amblyopic eye between 20/40 and 20/400 inclusive b. Visual acuity in the sound eye 20/32 or better c. Inter-eye acuity difference ≥ 2 logMAR lines (i.e., amblyopic eye acuity at least 3 lines worse than sound eye acuity) d) Gestational age \> 34 weeks and birth weight \> 1500 grams e) Parent willing to be contacted and has access to phone. If patients are enrolled in the myopic anisometropia amblyopia category, the following criteria must be met for the patients to be enrolled in the study. * Aged 3 to \<8 years * Best-corrected VA in the amblyopic eye of 20/40 to 20/400 inclusive * Best-corrected VA in the fellow eye of 20/40 or better * Magnitude of myopic anisometropia of \> 3.00 D * Intereye acuity difference of \> 3 logMAR lines * Amblyopia associated with myopic anisometropia * Has been wearing optimal spectacle correction for a minimum of four weeks

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuity Improvement12± 1 weeks after treatmentVisual acuity was measured with ATS-HOTV methods in logMAR. The larger amount means the worse acuity. Visual acuity improvement is defined as the change at the primary outcome follow-up visit from the baseline. (Note: Visual acuity improvement = Visual acuity at the baseline - Visual acuity at the 12-week follow-up) The larger amount of change indicates better improvement.

Countries

United States

Participant flow

Participants by arm

ArmCount
12-hour IO-therapy Glasses
wear IO-therapy glasses for 12-hour IO-therapy Glasses: 12-hour of 50% intermittent occlusion therapy on the fellow eye.
2
6-hour Patching
wear the eye patch for 6-hour patch: 6-hour of eye patch on the fellow eye
4
Deprivation Amblyopia
wear IO-therapy glasses depends on the severity of amblyopia. If severe, wear 12 hours; if moderate, wear 4 hours.
2
Myopic Anisometropic Amblyopia
wear IO-therapy glasses depends on the severity of amblyopia. If severe, wear 12 hours; if moderate, wear 4 hours.
3
Total11

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyLost to Follow-up2200
Overall Studythe device is too small for the patient.1000
Overall StudyWithdrawal by Subject1001

Baseline characteristics

Characteristic12-hour IO-therapy GlassesTotalMyopic Anisometropic AmblyopiaDeprivation Amblyopia6-hour Patching
Age, Continuous4.7 Year
STANDARD_DEVIATION 0.2
5.7 Year
STANDARD_DEVIATION 1.1
5.9 Year
STANDARD_DEVIATION 0.6
6.8 Year
STANDARD_DEVIATION 0.1
5.4 Year
STANDARD_DEVIATION 1.6
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants2 Participants0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
2 Participants9 Participants3 Participants1 Participants3 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants3 Participants3 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
2 Participants8 Participants0 Participants2 Participants4 Participants
Sex: Female, Male
Female
1 Participants6 Participants2 Participants1 Participants2 Participants
Sex: Female, Male
Male
1 Participants5 Participants1 Participants1 Participants2 Participants
visual acuity of amblyopic eye1.10 logMAR
STANDARD_DEVIATION 0.28
0.71 logMAR
STANDARD_DEVIATION 0.29
0.5 logMAR
STANDARD_DEVIATION 0.17
0.75 logMAR
STANDARD_DEVIATION 0.35
0.86 logMAR
STANDARD_DEVIATION 0.17

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 20 / 40 / 20 / 3
other
Total, other adverse events
0 / 20 / 40 / 20 / 3
serious
Total, serious adverse events
0 / 20 / 40 / 20 / 3

Outcome results

Primary

Visual Acuity Improvement

Visual acuity was measured with ATS-HOTV methods in logMAR. The larger amount means the worse acuity. Visual acuity improvement is defined as the change at the primary outcome follow-up visit from the baseline. (Note: Visual acuity improvement = Visual acuity at the baseline - Visual acuity at the 12-week follow-up) The larger amount of change indicates better improvement.

Time frame: 12± 1 weeks after treatment

ArmMeasureValue (MEAN)Dispersion
12-hour IO-therapy GlassesVisual Acuity Improvement0.05 logMARStandard Deviation 0.07
6-hour PatchingVisual Acuity Improvement0.17 logMARStandard Deviation 0.23
Deprivation AmblyopiaVisual Acuity Improvement0.05 logMARStandard Deviation 0.07
Myopic Anisometropic AmblyopiaVisual Acuity Improvement0.1 logMARStandard Deviation 0.26

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026